How researchers and non-profits are tackling childhood cancer
A recent Financial Times piece explains how mission-driven capital is bridging the translation gap in childhood cancer drug discovery.
The challenges of childhood cancer cannot be met by the traditional research model alone. Because these diseases are rare, the market has little reason to carry promising science through the risky early stages of drug discovery, leaving a translation gap that stalls discoveries before they reach patients. A recent Financial Times piece explains how C-Further is built to fill that gap, acting as an active, milestone-driven drug discovery engine rather than a conventional funder. Research grants are essential for creating the science, but it is mission-driven capital, with C-Further as a leading example, that turns that science into a tangible medicine.
